iCRT3 is primarily used in biomedical research as an inhibitor of the Wnt/β-catenin signaling pathway. This pathway plays a critical role in cell proliferation, differentiation, and stem cell regulation, and its dysregulation is associated with various cancers and developmental disorders. iCRT3 helps in studying the molecular mechanisms of this pathway by specifically disrupting the interaction between β-catenin and its transcriptional co-activators, thereby suppressing the expression of Wnt target genes. It is commonly applied in cancer research, particularly in models of colorectal, liver, and breast cancers where Wnt signaling is often hyperactive. By inhibiting this pathway, iCRT3 can reduce tumor cell growth and induce apoptosis in preclinical studies. Additionally, it is used to investigate tissue regeneration and stem cell behavior, offering insights into potential regenerative medicine strategies. Due to its cell permeability and reversible action, iCRT3 is suitable for in vitro studies in cell cultures and is sometimes used in zebrafish and mouse models for developmental biology research. Its selectivity makes it a valuable tool for probing Wnt-dependent processes without broadly affecting other signaling pathways.